LON:FAB Fusion Antibodies (FAB) Share Price, News & Analysis GBX 6.30 -0.40 (-5.97%) As of 03:22 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Fusion Antibodies Stock (LON:FAB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Fusion Antibodies alerts:Sign Up Key Stats Today's Range 6.30▼ 6.6250-Day Range 6.37▼ 9.5052-Week Range 2.80▼ 12Volume4,454 shsAverage Volume1.29 million shsMarket Capitalization£5.93 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewFusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications. The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue. The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation. Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process. The global monoclonal antibody therapeutics market was valued at $186 billion in 2021 and is forecast to surpass $445 billion in 2028, an increase at a CAGR of 13.2 per cent. for the period 2022 to 2028. Approximately 150 monoclonal antibody therapies are approved and marketed globally as of June 2022 with the top four antibody drugs each having sales of more than $3 bn in 2021. Read More… Remove Ads Receive FAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fusion Antibodies and its competitors with MarketBeat's FREE daily newsletter. Email Address FAB Stock News HeadlinesFusing two immune system proteins leads to a new method of generating antibodiesMarch 25, 2025 | msn.comEvommune Initiates Phase 2 Trial of IL-18 Targeted Fusion Protein, EVO301, in Adult Patients with Atopic DermatitisMarch 17, 2025 | finance.yahoo.comThe unusual signal flashing green againSomething fascinating happened in April... While a lot of Wall Street institutions were opening new positions in a falling stock, something different showed up on my screen. A special set of candles had just turned green - signaling the kind of momentum surge I'd seen only a handful of times before. What happened next? The stock soared 45% on the underlying stock in just a few weeks and 227% for anyone who traded the options. Naturally, there would have been smaller wins and those that would not have worked out, but this wasn't some penny stock or crypto play… It was ARM Holdings - a major semiconductor player that had just shed 9% of its value.March 31, 2025 | ProsperityPub (Ad)Fusion Antibodies Share Chat (FAB)January 7, 2025 | lse.co.ukFusion Antibodies Secures Grant to Boost R&DDecember 4, 2024 | msn.comFusion Antibody Share Chat (FAB)October 26, 2024 | lse.co.uk'Positive momentum' builds at Belfast's Fusion AntibodiesOctober 10, 2024 | msn.comFusion Antibodies Full Year 2024 Earnings: EPS Misses ExpectationsSeptember 7, 2024 | finance.yahoo.comSee More Headlines FAB Stock Analysis - Frequently Asked Questions How have FAB shares performed this year? Fusion Antibodies' stock was trading at GBX 7.16 at the beginning of 2025. Since then, FAB shares have decreased by 12.0% and is now trading at GBX 6.30. View the best growth stocks for 2025 here. How were Fusion Antibodies' earnings last quarter? Fusion Antibodies plc (LON:FAB) released its earnings results on Tuesday, November, 19th. The company reported ($0.80) earnings per share for the quarter. Fusion Antibodies had a negative net margin of 195.95% and a negative trailing twelve-month return on equity of 137.11%. How do I buy shares of Fusion Antibodies? Shares of FAB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Fusion Antibodies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fusion Antibodies investors own include 4D pharma (DDDD), Omega Diagnostics Group (ODX), Tullow Oil (TLW), Active Energy Group (AEG), B&M European Value Retail (BME), BP (BP) and Coats Group (COA). Company Calendar Last Earnings11/19/2024Today3/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:FAB CIKN/A Webfusionantibodies.com Phone+44-28-90432800FaxN/AEmployees48Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (4.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-4,103,138.16 Net Margins-195.95% Pretax MarginN/A Return on Equity-137.11% Return on Assets-63.78% Debt Debt-to-Equity Ratio2.40 Current Ratio3.87 Quick Ratio2.36 Sales & Book Value Annual Sales£2.09 million Price / Sales2.97 Cash FlowGBX 0.73 per share Price / Cash Flow9.02 Book ValueGBX 3.51 per share Price / Book1.88Miscellaneous Outstanding Shares94,055,867Free FloatN/AMarket Cap£6.23 million OptionableNot Optionable Beta0.49 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (LON:FAB) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fusion Antibodies plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Fusion Antibodies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.